METHODS
The Swedish Alzheimer Treatment Study (SATS) is a prospective, observational, multicenter study for longitudinal assessment of cholinesterase inhibitor (ChEI) therapy in clinical practice involving 1,021 participants diagnosed with mild-to-moderate AD (Mini-Mental State Examination score, 10-26) at the start of ChEI treatment (time of AD diagnosis). Of these, 143 were defi ned as having EOAD (onset <65 years), 874 LOAD (onset ≥65 years), and four missing age-at-onset; thus, 1,017 patients were included. As shown in Tables 1  and 2 , t-tests were performed to analyze two independent groups and 2 tests were conducted to analyze categorical variables. Cox proportional hazards regression was used to determine characteristics that aff ected the time from AD diagnosis to death: sex, apolipoprotein E genotype, solitary living, duration of AD, age at baseline, years of education, specifi c concomitant medications (antihypertensive/cardiac therapy, antidiabetic drugs, asthma medication, thyroid therapy, lipid-lowering agents, estrogens, nonsteroidal anti-infl ammatory drugs/acetylsalicylic acid, antidepressants, antipsychotics, and anxiolytics/sedatives/hypnotics), cognition (Alzheimer's Disease Assessment Scale-cognitive subscale [ADAS-cog]), and ADL (Instrumental Activities of Daily Living scale [IADL] and Physical Self-Maintenance Scale [PSMS]) at baseline, and rate of decline (Table 3) . In Figure 2 , a Kaplan-Meier graph with a log-rank test was used to illustrate the diff erences in survival time. One-way analysis of variance (ANOVA) with Bonferroni correction was used to compare the diff erences between the means (Figures 2-4 Proportion of deceased participants with EOAD and LOAD per year after the initiation of ChEI treatment (time of AD diagnosis). After 18 years of follow-up, 115 (80%) of the EOAD and 797 (91%) of the LOAD patients had died (P <0.001). The mean ± standard deviation time from diagnosis to death diff ered between individuals with EOAD and LOAD, 8.0 ± 3.4 years vs. 6.2 ± 3.1 years, (P < 0.001). Year 1 indicates a life-span after baseline of up to 1 year, year 2 indicates >1 to ≤2 years, year 3 indicates >2 to ≤3 years, etc.
AD, Alzheimer's disease; ChEI, cholinesterase inhibitor; EOAD, early-onset Alzheimer's disease; LOAD, late-onset Alzheimer's disease; SATS, Swedish Alzheimer Treatment Study. Kaplan-Meier graph of the distribution of time from the initiation of ChEI therapy (time of AD diagnosis) to death for four EOAD groups based on IADL score at baseline. A log-rank test found significant differences between the groups (P = 0.001).
For the deceased EOAD patients, the mean ± SD time from AD diagnosis to death differed between individuals with varying IADL score at baseline (five had missing data): 8 points (no impairment), (n = 13), 10.1 ± 2.8 years; 9-11 points (n = 34), 8.3 ± 3.6 years; 12-17 points (n = 28), 8.1 ± 3.0 years; and >17 points (n = 35), 7.1 ± 3.3 years, (P = 0.041).
AD, Alzheimer's disease; ChEI, cholinesterase inhibitor; EOAD, early-onset Alzheimer's disease; IADL, Instrumental Activities of Daily Living scale; SD, standard deviation.
Kaplan-Meier graph of the distribution of time from the initiation of ChEI therapy (time of AD diagnosis) to death for four EOAD groups based on IADL score at baseline. A log-rank test found signifi cant diff erences between the groups (P = 0.001). For the deceased EOAD patients, the mean ± SD time from AD diagnosis to death diff ered between individuals with varying IADL score at baseline (fi ve had missing data): 8 points (no impairment), (n = 13), 10.1 ± 2.8 years; 9-11 points (n = 34), 8.3 ± 3.6 years; 12-17 points (n = 28), 8.1 ± 3.0 years; and >17 points (n = 35), 7.1 ± 3.3 years, (P = 0.041).
AD, Alzheimer's disease; ChEI, cholinesterase inhibitor; EOAD, early-onset Alzheimer's disease; IADL, Instrumental Activities of Daily Living scale; SD, standard deviation. The deceased EOAD patients showed a faster mean (95% CI) annual decline in cognitive ability (ADAS-cog score), -5.9 (-7.5, -4.3) points, compared with the other groups, EOAD still alive, -1.6 (-3.1, -0.1) points; LOAD deceased, -3.2 (-3.8, -2.6) points; and LOAD still alive, -0.5 (-1.1, 0.1) points, (P < 0.001).
ADAS-cog, Alzheimer's Disease Assessment Scale-cognitive subscale; CI, confidence interval; EOAD, early-onset Alzheimer's disease; LOAD, late-onset Alzheimer's disease.
The deceased EOAD patients showed a faster mean (95% CI) annual decline in cognitive ability (ADAScog score), -5.9 (-7.5, -4.3) points, compared with the other groups, EOAD still alive, -1.6 (-3.1, -0.1) points; LOAD deceased, -3.2 (-3.8, -2.6) points; and LOAD still alive, -0.5 (-1.1, 0.1) points, (P < 0.001).
ADAS-cog, Alzheimer's Disease Assessment Scale-cognitive subscale; CI, confi dence interval; EOAD, early-onset Alzheimer's disease; LOAD, late-onset Alzheimer's disease. No significant difference in mean (95% CI) basic ADL capacity (PSMS score) change/year was observed in EOAD between the deceased participants -1.3 (-1.6, -0.9) points and those still alive -0.6 (-1.0, -0.3) points. In LOAD, the deceased group exhibited a more rapid mean annual deterioration in basic ADL, -1.3 (-1.5, -1.2) points, compared with the patients still alive, -0.4 (-0.6, -0.1) points, (P = 0.004).
ADL, activities of daily living; CI, confidence interval; EOAD, early-onset Alzheimer's disease; LOAD, No signifi cant diff erence in mean (95% CI) basic ADL capacity (PSMS score) change/year was observed in EOAD between the deceased participants -1.3 (-1.6, -0.9) points and those still alive -0.6 (-1.0, -0.3) points. In LOAD, the deceased group exhibited a more rapid mean annual deterioration in basic ADL, -1.3 (-1.5, -1.2) points, compared with the patients still alive, -0.4 (-0.6, -0.1) points, (P = 0.004).
ADL, activities of daily living; CI, confi dence interval; EOAD, early-onset Alzheimer's disease; LOAD, late-onset Alzheimer's disease; PSMS, Physical Self-Maintenance Scale. AD, Alzheimer's disease; ADAS-cog, Alzheimer's Disease Assessment Scalecognitive subscale; APOE, apolipoprotein E; IADL, Instrumental Activities of Daily Living scale; NSAIDs, nonsteroidal anti-infl ammatory drugs; PSMS, Physical Self-Maintenance Scale.
RESULTS
AD, Alzheimer's disease; ADAS-cog, Alzheimer's Disease Assessment Scalecognitive subscale; APOE, apolipoprotein E; IADL, Instrumental Activities of Daily Living scale; NSAIDs, nonsteroidal anti-infl ammatory drugs; PSMS, Physical Self-Maintenance Scale. Table 2 . Late-onset AD, baseline characteristics (n = 874)
Page 6 (14) Number of apolipoprotein E ε4 alleles, duration of AD, years of education, IADL score rate of change per year, and specifi c concomitant medications, with the exception of antihypertensives/cardiac therapy and antidiabetics, were not signifi cant factors in the models. Male living with a family member was the reference category.
Hazard ratios are expressed per 1 unit increase for continuous variables and for the condition present for categorized variables.
